Doravirine
57 interactions 244 cited referencesDoravirine is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults who have not been treated with other HIV medications. It is also used to replace current medication therapy in certain people already taking HIV medications. Doravirine is in a class of medications called non… Read the full Doravirine drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Doravirine Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Doravirine Pacritinib Vonjo® Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Pexidartinib Turalio Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Doravirine Repotrectinib Augtyro Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Rifabutin Mycobutin Reduced doravirine exposure, reduced efficacy and an increased risk of doravirine resistance Details Doravirine Sotorasib Lumakras Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Doravirine Telotristat Ethyl Xermelo Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Thioridazine Reduced doravirine exposure and reduced efficacy of doravirine Details Doravirine Voriconazole Vfend Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects Details Doravirine Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Doravirine Nafcillin Injection Unipen® Injection Reduced doravirine exposure and reduced efficacy of doravirine DetailsModerate
Doravirine Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Doravirine Kratom Increased CYP3A substrate exposure Details Doravirine Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Doravirine Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist